Publication Author: Weatherald J
Filter by Author:
Health-related Quality of Life and Exercise Capacity in Double Lung Transplant Recipients With Baseline Lung Allograft Dysfunction.
Rullay A, Kaur K, Holman J, van den Bosch LC, Weinkauf JG, Nagendran J, Varughese RA, Hirji AS, Lien DC, Weatherald JC, Halloran KM.
Cardiopulmonary Exercise Testing in Pulmonary Hypertension.
Dmytriiev K, Stickland MK, Weatherald J.
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.
Weatherald J, Fleming TR, Wilkins MR, Cascino TM, Psotka MA, Zamanian R, Seeger W, Galiè N, Gomberg-Maitland M.
Sex Differences in Venous Thromboembolism after Covid-19 Infection: A Retrospective Population-based Matched Cohort Study.
Weatherald J, Wen C, Stickland MK, Damant R, Smith MP, Soril LJ, Zhang Z, D'Souza AG, Rennert-May E, Leal J, Lam GY.
Phenotypes in Pulmonary Hypertension.
Weatherald J, Hemnes AR, Maron BA, Mielniczuk LM, Gerges C, Price LC, Hoeper MM, Humbert M.
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe.
Budhram B, Zamanian RT, Weatherald J.
COVID-19 Pandemic on COPD Healthcare Utilization, Exacerbations and Mortality: A Population Study.
Lam GY, Wen C, Ronksley PE, Bakal JA, Bhutani M, Soril LJJ, Stickland MK, Gross DP, Weatherald J.
The clinical impact of heart failure with preserved ejection fraction in interstitial lung diseases.
Zanini U, Ferrara G, Moitra S, Varughese R, Kalluri M, Weatherald J.
Increased Virtual Visits to Physicians During the COVID-19 Pandemic and Estimated Impact on Physician Compensation: The Case of Lung and Colorectal Cancers, Chronic Obstructive Pulmonary Diseases, and Heart Failure in Alberta, Canada.
Thanh NX, Waye A, Stewart D, Weatherald J, Lam GY, Stickland MK, Hill MD, Choy J, Chuck AW, Wasylak T.
Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study.
Weatherald J, Nathan SD, El-Kersh K, Argula RG, DuBrock HM, Rischard FP, Cassady SJ, Tarver J, Levine DJ, Tapson VF, Deng C, Shen E, Das M, Waxman AB.
Constructing the Framework for Disease Modification in Pulmonary Arterial Hypertension.
Zamanian RT, Weatherald J, Sweatt AJ, Hemnes A, Rashid M, Psotka MA, Bogaard HJ, de Jesus Perez V.
Pulmonary Hypertension in Connective Tissue Diseases Other than Systemic Sclerosis.
Budhram B, Weatherald J, Humbert M.
Treatments for pulmonary arterial hypertension: navigating through a network of choices.
Pitre T, Weatherald J, Humbert M.
POINT: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? Yes.
Weatherald J, Sitbon O.
“I Had to Know About It, I Had to Find It, I Had to Know How to Access it”: Experiences of Access to Rehabilitation Services Among People Living with Long COVID.
Hung P, Brehon K, Miciak M, Brown DA, Bostick G, Brown C, Churchill K, Hall M, Hoddinott L, Hudon A, Hunter S, Perreault K, Wieler M, Skolnik K, Lam GY, Weatherald J, Gross DP.
Randomized Trial Of Routine Versus On-demand Intraoperative Extracorporeal Membrane Oxygenation In Lung Transplantation: A Feasibility Study.
Nasir B, Weatherald J, Ramsay T, Cypel M, Donahoe L, Durkin C, Schisler T, Nagendran J, Liberman M, Landry C, Overbeek C, Moore A, Ferraro P.
Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative’s Real-world Evidence Working Group.
Morland K, Gerges C, Elwing J, Visovatti SH, Weatherald J, Gillmeyer KR, Sahay S, Mathai SC, Boucly A, Williams PG, Harikrishnan S, Minty EP, Hobohm L, Jose A, Badagliacca R, Lau EMT, Jing ZC, Vanderpool RR, Fauvel C, Leonidas Alves J Jr, Strange G, Pulido T, Qian J, Li M, Mercurio V, Zelt JGE, Moles VM, Cirulis MM, Nikkho SM, Benza RL, Elliott CG.
“None of us are lying”: an interpretive description of the search for legitimacy and the journey to access quality health services by individuals living with Long COVID.
Brehon K, Miciak M, Hung P, Chen SP, Perreault K, Hudon A, Wieler M, Hunter S, Hoddinott L, Hall M, Churchill K, Brown DA, Brown CA, Bostick G, Skolnik K, Lam G, Weatherald J, Gross DP.
Ambitions for Pulmonary Arterial Hypertension Composite End Points: A Chain Is Only as Strong as Its Weakest Link.
Zelt JGE, Weatherald J, Mathai SC.
